ABCAM Plc ABC Director/PDMR Shareholding

  ABCAM Plc (ABC) - Director/PDMR Shareholding

RNS Number : 7758Q
09 November 2012

For immediate release 9 November 2012

                                  ABCAM PLC

                          ("Abcam" or "the Company")

                 Director/PDMR dealing: Share Incentive Plan

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein
research tools, announces that following completion of three years of
continued employment since the award of Free Shares under the Share Incentive
Plan on 9 November 2009, the risk of forfeiture attached to these shares has
now been removed, resulting in an increase in the beneficial holding of each
Director/PDMR as follows:

           Name        Free Shares now transferred to Total      Percentage of
                       beneficial ownership           subsequent share capital
 Executive Jonathan                             1,655 27,932,287        14.08%
Directors: Milner
           Jim Warwick                          1,655  2,942,087         1.48%
           Jeff Iliffe                          1,655     24,287         0.01%
     PDMR: Mark                                 1,655      5,760        0.003%
           Jane Cooke                           1,655     10,676        0.005%
           Philippe                             1,655      9,377        0.004%
           Ed Ralph                             1,655    365,007        0.184%

For further information please contact:

Abcam                                               + 44 (0) 1223 696 000
Jeff Iliffe, Chief Financial Officer

Numis Securities - Nominated Adviser & Joint Broker + 44 (0) 20 7260 1000
Michael Meade - Nominated Adviser
James Black - Corporate Broking

Peel Hunt LLP - Joint Broker                        + 44 (0) 20 7418 8900
Andy Crossley - Corporate Broking

Buchanan                                            + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools.
These tools enable life scientists to analyse components of living cells at
the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK),
Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan),
Hangzhou and Hong Kong (both in China), allowing it to serve a global customer
base in over 130 countries. Abcam employs over 600 staff across its eight
operating companies.

Abcam now has an online catalogue of over 99,000 products sourced from over
400 suppliers. The catalogue includes a growing range of non-primary antibody
products such as secondaries, proteins, peptides, lysates, immunoassays and
other kits. Products are available for life science research and distributed
to academic and commercial users. A highly developed eCommerce platform, which
includes regional websites for the Chinese and Japanese markets, allows
customers to access up-to-date and detailed technical product data sheets at
the Company's website

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol
ABC. The Company's vision is to be the world's leading life science tools

                     This information is provided by RNS
           The company news service from the London Stock Exchange


RDSFKLFBLFFEFBV -0- Nov/09/2012 11:58 GMT
Press spacebar to pause and continue. Press esc to stop.